Saturday 17 October 2026
Export IRLA’s income statement to Excel — free account
Quince Therapeutics, Inc.
IRLA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 81.9%, free cash flow fell 63.7% and total debt rose 28.2%, each against the same quarter a year earlier.
32.17
1.06
−3.19%
Follow IRLA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(247.78%) | 3,016.49% | (192.90%) | 784.09% | |
| (48.20%) | (80.75%) | (49.42%) | (76.68%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,509.78%) | 425.53% | (190.28%) | (80.12%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(144.47) | (166.77) | (86.52) | (7.65) | |
Free Cash Flow |
(38.98) | (41.78) | (39.45) | (46.92) | |
Capital Expenditures |
(0.48) | (0.35) | — | — | |
| Other line items | |||||
Cash ROIC |
(86.87%) | (10,603.30%) | (116.60%) | (58.18%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.04 | (0.06) | (0.02) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.68 | 0.49 | 1.19 | 0.51 | |
Depreciation/Fixed assets |
(1.94) | (1.47) | (1.05) | (0.66) | |
Capex/Depreciation |
0.40 | 0.40 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(142.68) | (165.37) | (86.52) | (7.65) | |
Capex per Share |
(1.78) | (1.41) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates